TrialCurveKEYNOTE-042 China (5-year update): reconstructed Kaplan–Meier curves
Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Int J Cancer. 2025 Dec 31;158(9):2429–39. doi: 10.1002/ijc.70265 |
|---|---|
| DOI | 10.1002/ijc.70265 |
| Registry | NCT03850444 |
| Phase | Phase 3 |
| Conditions | Non-small Cell Lung Cancer |
| Interventions | pembrolizumab, carboplatin, paclitaxel, pemetrexed |
| Sponsor | Merck Sharp & Dohme LLC |
| Enrolment | 262 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — PD-L1 TPS >=50%
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembrolizumab 23.9 months; Chemotherapy 13.4 months. Survival at 18 months: Pembrolizumab 61%; Chemotherapy 39%. Hazard ratio Pembrolizumab vs Chemotherapy 0.65 (95% CI 0.45–0.92).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembrolizumab | 72 | 58 | 23.9 |
| Chemotherapy | 74 | 67 | 13.4 |
- Pembrolizumab vs Chemotherapy: reconstructed HR 0.65 (95% CI 0.45–0.92)
Landmark survival (reconstructed)
| Time | Pembrolizumab | Chemotherapy |
|---|---|---|
| 6 mo | 81.9% | 83.8% |
| 12 mo | 70.8% | 55.4% |
| 18 mo | 61.1% | 39.2% |
| 24 mo | 50.0% | 29.7% |
| 36 mo | 33.3% | 18.4% |
| 48 mo | 24.7% | 15.5% |
| 60 mo | 18.0% | 8.2% |
Checks against the published figure
- Pembrolizumab median: printed 24.5, reconstructed 23.9 pass
- Chemotherapy median: printed 13.8, reconstructed 13.4 pass
- Pembrolizumab events: printed 58, reconstructed 58 pass
- Pembrolizumab n: printed 72, reconstructed 72 pass
- Chemotherapy events: printed 67, reconstructed 67 pass
- Chemotherapy n: printed 74, reconstructed 74 pass
- hazard ratio (direction inferred): printed 0.65, reconstructed 0.646 pass
Overall survival — PD-L1 TPS >=20%
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembrolizumab 21.8 months; Chemotherapy 13.4 months. Survival at 18 months: Pembrolizumab 58%; Chemotherapy 39%. Hazard ratio Pembrolizumab vs Chemotherapy 0.68 (95% CI 0.50–0.92).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembrolizumab | 101 | 80 | 21.8 |
| Chemotherapy | 103 | 90 | 13.4 |
- Pembrolizumab vs Chemotherapy: reconstructed HR 0.68 (95% CI 0.50–0.92)
Landmark survival (reconstructed)
| Time | Pembrolizumab | Chemotherapy |
|---|---|---|
| 6 mo | 81.2% | 84.3% |
| 12 mo | 69.2% | 53.5% |
| 18 mo | 58.2% | 38.7% |
| 24 mo | 46.1% | 28.7% |
| 36 mo | 30.1% | 17.4% |
| 48 mo | 23.0% | 15.4% |
| 60 mo | 19.4% | 10.2% |
Checks against the published figure
- Pembrolizumab median: printed 21.9, reconstructed 21.8 pass
- Chemotherapy median: printed 13.5, reconstructed 13.4 pass
- Pembrolizumab events: printed 81, reconstructed 80 pass
- Pembrolizumab n: printed 101, reconstructed 101 pass
- Chemotherapy events: printed 90, reconstructed 90 pass
- Chemotherapy n: printed 103, reconstructed 103 pass
- hazard ratio (direction inferred): printed 0.67, reconstructed 0.677 pass
Overall survival — PD-L1 TPS >=1%
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembrolizumab 20.3 months; Chemotherapy 13.5 months. Survival at 18 months: Pembrolizumab 57%; Chemotherapy 41%. Hazard ratio Pembrolizumab vs Chemotherapy 0.68 (95% CI 0.52–0.89).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembrolizumab | 128 | 102 | 20.3 |
| Chemotherapy | 134 | 117 | 13.5 |
- Pembrolizumab vs Chemotherapy: reconstructed HR 0.68 (95% CI 0.52–0.89)
Landmark survival (reconstructed)
| Time | Pembrolizumab | Chemotherapy |
|---|---|---|
| 6 mo | 80.4% | 82.6% |
| 12 mo | 68.5% | 52.8% |
| 18 mo | 56.7% | 40.5% |
| 24 mo | 44.1% | 27.5% |
| 36 mo | 28.4% | 16.2% |
| 48 mo | 22.1% | 13.0% |
| 60 mo | 19.0% | 9.6% |
Checks against the published figure
- Pembrolizumab median: printed 20.2, reconstructed 20.3 pass
- Chemotherapy median: printed 13.5, reconstructed 13.5 pass
- Pembrolizumab events: printed 103, reconstructed 102 pass
- Pembrolizumab n: printed 128, reconstructed 128 pass
- Chemotherapy events: printed 117, reconstructed 117 pass
- Chemotherapy n: printed 134, reconstructed 134 pass
- hazard ratio (direction inferred): printed 0.66, reconstructed 0.68 pass
Overall survival — PD-L1 TPS 1%-49%
From figure panel D · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Pembrolizumab 19.0 months; Chemotherapy 10.4 months. Survival at 18 months: Pembrolizumab 52%; Chemotherapy 41%. Hazard ratio Pembrolizumab vs Chemotherapy 0.74 (95% CI 0.49–1.12).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Pembrolizumab | 56 | 43 | 19.0 |
| Chemotherapy | 60 | 49 | 10.4 |
- Pembrolizumab vs Chemotherapy: reconstructed HR 0.74 (95% CI 0.49–1.12)
Landmark survival (reconstructed)
| Time | Pembrolizumab | Chemotherapy |
|---|---|---|
| 6 mo | 79.9% | 82.7% |
| 12 mo | 66.9% | 48.5% |
| 18 mo | 52.0% | 41.3% |
| 24 mo | 37.2% | 26.7% |
| 36 mo | 20.4% | 13.4% |
| 48 mo | 20.4% | 11.5% |
| 60 mo | 20.4% | 11.5% |
Checks against the published figure
- Pembrolizumab median: printed 18.6, reconstructed 19 pass
- Chemotherapy median: printed 10.4, reconstructed 10.4 pass
- Pembrolizumab events: printed 45, reconstructed 43 pass
- Pembrolizumab n: printed 56, reconstructed 56 pass
- Chemotherapy events: printed 50, reconstructed 49 pass
- Chemotherapy n: printed 60, reconstructed 60 pass
- hazard ratio (direction inferred): printed 0.69, reconstructed 0.744 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/keynote-042-china-5-year-update-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/keynote-042-china-5-year-update-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Int J Cancer. 2025 Dec 31;158(9):2429–39. doi: 10.1002/ijc.70265 doi:10.1002/ijc.70265. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/keynote-042-china-5-year-update
Report a problem with these data
Related trials
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- TOPICAL: Overall survival; Progression-free survival
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
- CA209-7AL: Progression-free survival
- ETER701: Overall survival; Progression-free survival (PFS)
- LUNGSTAR: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials